GH Research (NASDAQ:GHRS) Earns “Buy” Rating from HC Wainwright

GH Research (NASDAQ:GHRS)‘s stock had its “buy” rating restated by investment analysts at HC Wainwright in a research note issued on Wednesday,Benzinga reports. They currently have a $40.00 price objective on the stock. HC Wainwright’s price objective would indicate a potential upside of 315.80% from the stock’s previous close.

A number of other research analysts have also recently issued reports on the company. Canaccord Genuity Group lowered their price objective on GH Research from $31.00 to $28.00 and set a “buy” rating for the company in a research note on Monday. JMP Securities reaffirmed a “market outperform” rating and issued a $39.00 price target on shares of GH Research in a research report on Wednesday, September 4th.

GH Research Trading Down 12.1 %

Shares of GHRS stock opened at $9.62 on Wednesday. The company’s fifty day moving average price is $7.90 and its 200-day moving average price is $10.33. The stock has a market cap of $500.53 million, a PE ratio of -12.18 and a beta of 0.74. GH Research has a 12 month low of $5.05 and a 12 month high of $14.99.

GH Research (NASDAQ:GHRS) last announced its quarterly earnings data on Tuesday, September 3rd. The company reported ($0.20) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.03. On average, sell-side analysts forecast that GH Research will post -0.78 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in GH Research stock. Lynx1 Capital Management LP boosted its stake in GH Research PLC (NASDAQ:GHRS) by 80.1% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 3,310,563 shares of the company’s stock after purchasing an additional 1,471,946 shares during the period. GH Research makes up approximately 9.1% of Lynx1 Capital Management LP’s holdings, making the stock its 6th largest position. Lynx1 Capital Management LP owned about 6.36% of GH Research worth $35,291,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 56.90% of the company’s stock.

GH Research Company Profile

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).